Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism


Author index

Page Path
Sun-Gi Kim  (Kim SG) 1 Article
Obesity and Metabolism
Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
Sun-Gi Kim, Byung-Kwon Kim, Kyumin Kim, Sungsoon Fang
Endocrinol Metab. 2016;31(4):500-504.   Published online December 20, 2016
  • 5,376 View
  • 73 Download
  • 32 Web of Science
  • 33 Crossref
AbstractAbstract PDFPubReader   

Nonalcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is accumulated in the liver without alcohol consumption. NAFLD is the most common liver disorder in advanced countries. NAFLD is a spectrum of pathology involving hepatic steatosis with/without inflammation and nonalcoholic steatohepatitis with accumulation of hepatocyte damage and hepatic fibrosis. Recent studies have revealed that NAFLD results in the progression of cryptogenic cirrhosis that leads to hepatocarcinoma and cardiovascular diseases such as heart failure. The main causes of NAFLD have not been revealed yet, metabolic syndromes including obesity and insulin resistance are widely accepted for the critical risk factors for the pathogenesis of NAFLD. Nuclear receptors (NRs) are transcriptional factors that sense environmental or hormonal signals and regulate expression of genes, involved in cellular growth, development, and metabolism. Several NRs have been reported to regulate genes involved in energy and xenobiotic metabolism and inflammation. Among various NRs, farnesoid X receptor (FXR) is abundantly expressed in the liver and a key regulator to control various metabolic processes in the liver. Recent studies have shown that NAFLD is associated with inappropriate function of FXR. The impact of FXR transcriptional activity in NAFLD is likely to be potential therapeutic strategy, but still requires to elucidate underlying potent therapeutic mechanisms of FXR for the treatment of NAFLD. This article will focus the physiological roles of FXR and establish the correlation between FXR transcriptional activity and the pathogenesis of NAFLD.


Citations to this article as recorded by  
  • Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo
    Hongshan Li, Yingfei Xi, Xin Xin, Qin Feng, Yiyang Hu
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer
    Yanguang Hou, Jiachen Liu, Shiyu Huang, Lei Wang, Juncheng Hu, Xiuheng Liu
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
    Chander K. Negi, Pavel Babica, Lola Bajard, Julie Bienertova-Vasku, Giovanni Tarantino
    Metabolism.2022; 126: 154925.     CrossRef
  • FXR: structures, biology, and drug development for NASH and fibrosis diseases
    Si-yu Tian, Shu-ming Chen, Cheng-xi Pan, Yong Li
    Acta Pharmacologica Sinica.2022; 43(5): 1120.     CrossRef
  • Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
    Aamir Bashir, Ajay Duseja, Arka De, Manu Mehta, Pramil Tiwari
    Liver Research.2022; 6(2): 72.     CrossRef
  • The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice
    Jamal Nasser Saleh Al-maamari, Mahardian Rahmadi, Sisca Melani Panggono, Devita Ardina Prameswari, Eka Dewi Pratiwi, Chrismawan Ardianto, Santhra Segaran Balan, Budi Suprapti
    Journal of Basic and Clinical Physiology and Pharmacology.2021; 32(4): 637.     CrossRef
  • Co‑administration of obeticholic acid and simvastatin protects against high‑fat diet‑induced non‑alcoholic steatohepatitis in mice
    Wen-Cong Li, Su-Xian Zhao, Wei-Guang Ren, Yu-Guo Zhang, Rong-Qi Wang, Ling-Bo Kong, Qing-Shan Zhang, Yue-Min Nan
    Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
  • Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis
    Hongshan Li, Yingfei Xi, Xin Xin, Huajie Tian, Yiyang Hu
    Nutrition & Metabolism.2020;[Epub]     CrossRef
  • Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
    Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
    Pharmacological Research.2020; 159: 104984.     CrossRef
  • Farnesoid X Receptor Activation Protects Liver From Ischemia/Reperfusion Injury by Up‐Regulating Small Heterodimer Partner in Kupffer Cells
    Dan Jin, Tianfei Lu, Ming Ni, Han Wang, Jiang Zhang, Chenpeng Zhong, Chuan Shen, Jun Hao, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski, Jianjun Zhang, Ning Xu, Yuan Zhai
    Hepatology Communications.2020; 4(4): 540.     CrossRef
  • Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota–bile acid–farnesoid X receptor axis
    Hongshan Li, Yingfei Xi, Xin Xin, Huajie Tian, Yiyang Hu
    Biomedicine & Pharmacotherapy.2020; 124: 109915.     CrossRef
  • An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
    Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu, Yunlun Li
    BioMed Research International.2020; 2020: 1.     CrossRef
  • Intestinal Barrier Function–Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota
    Yizhe Cui, Qiuju Wang, Renxu Chang, Xiaocui Zhou, Chuang Xu
    Journal of Agricultural and Food Chemistry.2019; 67(10): 2754.     CrossRef
  • A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters
    Mao-xu Ge, Wei-xiao Niu, Jin-feng Ren, Shi-ying Cai, Dong-ke Yu, Hong-tao Liu, Na Zhang, Yi-xuan Zhang, Yu-cheng Wang, Rong-guang Shao, Ju-xian Wang, Hong-wei He
    Acta Pharmacologica Sinica.2019; 40(7): 895.     CrossRef
  • Consenso mexicano de la enfermedad por hígado graso no alcohólico
    R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrer
    Revista de Gastroenterología de México.2019; 84(1): 69.     CrossRef
  • Fish oil alleviates circadian bile composition dysregulation in male mice with NAFLD
    Yang Liu, Qi Li, Hualin Wang, Xiuju Zhao, Na Li, Hongyu Zhang, Guoxun Chen, Zhiguo Liu
    The Journal of Nutritional Biochemistry.2019; 69: 53.     CrossRef
  • Effects of sanshoamides and capsaicinoids on plasma and liver lipid metabolism in hyperlipidemic rats
    Zhaojun Chen, Yongxiang Liu, Hui Wang, Zhongai Chen, Jia Liu, Hui Liu
    Food Science and Biotechnology.2019; 28(2): 519.     CrossRef
  • The Mexican consensus on nonalcoholic fatty liver disease
    R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrer
    Revista de Gastroenterología de México (English Edition).2019; 84(1): 69.     CrossRef
  • Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study
    Ning Liu, Jiao Feng, Yang Lv, Qing Liu, Jingfan Deng, Yujing Xia, Chuanyong Guo, Yingqun Zhou
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Essential role of nuclear receptors for the evaluation of the benefits of bioactive herbal extracts on liver function
    Fengling Wang, Yifan Wu, Xiaoting Xie, Jing Sun, Weidong Chen
    Biomedicine & Pharmacotherapy.2018; 99: 798.     CrossRef
  • Maternal obesity has sex‐dependent effects on insulin, glucose and lipid metabolism and the liver transcriptome in young adult rat offspring
    Consuelo Lomas‐Soria, Luis A. Reyes‐Castro, Guadalupe L. Rodríguez‐González, Carlos A. Ibáñez, Claudia J. Bautista, Laura A. Cox, Peter W. Nathanielsz, Elena Zambrano
    The Journal of Physiology.2018; 596(19): 4611.     CrossRef
  • Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR/AMPK signaling pathway in vivo
    Lingli Zheng, Lianhong Yin, Lina Xu, Yan Qi, Hua Li, Youwei Xu, Xu Han, Kexin Liu, Jinyong Peng
    Biomedicine & Pharmacotherapy.2018; 97: 481.     CrossRef
  • New therapeutic perspectives in non-alcoholic steatohepatitis
    Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez
    Gastroenterología y Hepatología (English Edition).2018; 41(2): 128.     CrossRef
  • Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
    Valerio Nobili, Anna Alisi, Antonella Mosca, Claudia Della Corte, Silvio Veraldi, Rita De Vito, Cristiano De Stefanis, Valentina D'Oria, Joerg Jahnel, Evelyn Zohrer, Eleonora Scorletti, Christopher D. Byrne
    Liver International.2018; 38(2): 342.     CrossRef
  • The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives
    Stefano Gitto, Valeria Guarneri, Alessandro Sartini, Pietro Andreone
    Expert Review of Gastroenterology & Hepatology.2018; 12(2): 165.     CrossRef
  • Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR
    Verena Hiebl, Angela Ladurner, Simone Latkolik, Verena M. Dirsch
    Biotechnology Advances.2018; 36(6): 1657.     CrossRef
  • Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica
    Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez
    Gastroenterología y Hepatología.2018; 41(2): 128.     CrossRef
  • Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease
    Qinwei Yu, Zhenzhou Jiang, Luyong Zhang
    Pharmacology & Therapeutics.2018; 190: 81.     CrossRef
  • Hippocampal FXR plays a role in the pathogenesis of depression: A preliminary study based on lentiviral gene modulation
    Wei-Guan Chen, Jia-Xuan Zheng, Xi Xu, Yu-Ming Hu, Yu-Min Ma
    Psychiatry Research.2018; 264: 374.     CrossRef
  • Bile acid receptors and the kidney
    Michal Herman-Edelstein, Talia Weinstein, Moshe Levi
    Current Opinion in Nephrology and Hypertension.2018; 27(1): 56.     CrossRef
  • Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver
    Amir Hajighasem, Parvin Farzanegi, Zohreh Mazaheri, Marjan Naghizadeh, Ghoncheh Salehi
    PeerJ.2018; 6: e5522.     CrossRef
  • Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
    Marco Poeta, Luca Pierri, Pietro Vajro
    Children.2017; 4(8): 66.     CrossRef
  • Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review
    S Singh, KK Kharbanda
    Archives of Hepatitis Research.2017; 3(1): 029.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism